News >

Expert Discusses Ongoing Advances With Immunotherapy in CRC

Danielle Bucco
Published: Thursday, Sep 28, 2017

Tanios Bekaii-Saab, MD

Tanios Bekaii-Saab, MD
Microsatellite instability-high (MSI-H) tumors comprise approximately 4% of patients with colorectal cancer (CRC), and those patients are likely to respond to checkpoint inhibitors, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), according to Tanios Bekaii-Saab, MD.

on Gastrointestinal Malignancies, Bekaii-Saab discussed the emerging role of immunotherapy in patients with MSI-H tumors and beyond.

OncLive: Please provide an overview of your presentation.

Bekaii-Saab: My discussion focused on the role of immunotherapy, specifically PD-1 and PD-L1 inhibitors, in patients who have MSI-H tumors. Those are cancers that lack the expression of some proteins. This is a surrogate marker for tumors that are loaded with mutations, such as hypermutated tumors.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x